Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sapacitabine: Phase I data

In a Phase I trial in 47 patients with advanced leukemias or myelodysplastic syndromes (MDS), the

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE